Pharmaceuticals

Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication

SHANGHAI , July 18, 2023 /PRNewswire/ -- The product of Fosun Kite Biotechnology Co., Ltd., jointly established by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Kite Pharma ofthe United States (trade name: Yikaida®) for the treatment of adult large B-cell lymphoma (r/r LBCL) ("this new ind...

2023-07-19 10:42 1831

Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet

SEOUL, South Korea, July 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical obtained approval for a SGLT-2 inhibitor+metformin combination drug in just one month after the release of Envlo Tab., the 1st SGLT-2 inhibitor by Korea, expanding its product portfolio. Daewoong Pharmaceutical (Jeon Sen...

2023-07-19 08:52 2381

First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib

MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstad...

2023-07-19 05:00 2334

Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND

SHANGHAI, July 18, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 9MW2921 for advanced solid tumor was approved by the National Medical Products Administration (NMPA). 9MW2921 is dev...

2023-07-19 00:00 2857

Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility

INCHEON, South Korea, July 18, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940), a global contract development and manufacturing organization (CDMO), today released its 2023 Environmental, Social and Governance (ESG) Report. The annual report outlines the company's progress toward its sustain...

2023-07-18 19:00 1923

Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis

* DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics * Acquisition includes DTx-1252 with the potential to deliver a transformative medicine to Charcot-Marie-Tooth Disease Type 1A (CMT1A) patients * Acquisitio...

2023-07-18 15:00 5080

Join Taipei City's Thriving Health Industry: Registration for "Win A Greater Health" Pitch Contest Starts Now!

TAIPEI, July 18, 2023 /PRNewswire/ -- The Taipei City Government's Department of Economic Development is taking proactive steps to attract international startups and foster collaboration with local businesses through its "Talent Exchange Program". In line with this initiative, they have establish...

2023-07-18 11:35 2003

SK Biopharmaceuticals Makes Big Bets to be 'Big Biotech'

SK Biopharmaceuticals CEO Donghoon Lee maps out its medium to long-term strategy at a press conference SK Biopharmaceuticals mobilizes its cutting-edge modality platforms of radiopharmaceutical therapy (RPT), targeted protein degradation (TPD), and cell and gene therapy (CGT) aligning with its v...

2023-07-18 09:00 1688

Antengene Announces First Patient Dosed in the Nivolumab Combination Portion of the Clinical Study Evaluating the ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors in the United States

-  ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor.  Antengene has exclusive global rights to develop, commercialize, and manufacture ATG-017 -  The combination portion of the ERASER study, the first-in-human (FIH) study of ATG-017, was designed to evaluate the safety/tole...

2023-07-18 08:30 2349

Qilian International Holding Group Ltd Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

JIUQUAN, China, July 17, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (NASDAQ: QLI) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, received notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq"), datedJuly ...

2023-07-17 22:30 5259

BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program

* Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS * Underpinned by proprietary IV-formulated, Brain-targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiNTM) platform * BIORCHESTRA to receive in-kind products and services from Merck Group CAMBRIDGE, Mas...

2023-07-17 21:28 2089

ALZHEIMER'S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023

AMSTERDAM, July 17, 2023 /PRNewswire/ -- The data reported today by Eli Lilly from theTRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer's disease demonstrate an important  advancement in Alzheimer's research and treatment. The full Phase 3 data was reported at the Alzh...

2023-07-17 21:15 2292

GeneQuantum and InxMed have reached a technology licensing collaboration, providing strong support for innovative ADC drug research and development

SUZHOU, China, July 17, 2023 /PRNewswire/ -- On July 14, 2023, GeneQuantum, a leading pioneer committed to innovative bioconjugation technology, and InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors...

2023-07-17 17:00 1499

Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong * XPOVIO® has received regulatory approvals in 41 countries and regions  includingthe United States, Israel, the United Kingdom, the European Union (the 27 member countries includingFrance and Italy), Canada, Norw...

2023-07-17 08:30 2753

Red Marrow Peptide-A Major Breakthrough in Human Health Engineering

BEIJING, July 14, 2023 /PRNewswire/ -- 1.8 g! This figure refers to the weight of red marrow which can be extracted from a 100 kg young yak growing in no-human zone ofQinghai and enjoys the reputation of "the key of cardiovascular health". It is called the most perfect "blood scavenger", ...

2023-07-14 12:51 2138

Menarini Silicon Biosystems announces the launch of its new CELLSEARCH® CTC test with the DLL3 biomarker for small cell lung cancer

This new CELLSEARCH Circulating Tumor Cell (CTC) test is now available as a Research Use Only (RUO) lab service inNorth America and Europe. It is currently intended for basic and pharmaceutical research and it is the latest example of how Menarini Silicon Biosystems continues its development of c...

2023-07-13 20:00 3074

Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, July 13, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2023-07-13 18:11 4166

Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences

HONG KONG, Germantown, Md. and SUZHOU, China, July 12, 2023 /PRNewswire/ --  Sirnaomics Ltd.(the "Company", stock code: 2257, together with its subsidiaries, the"Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, hereby...

2023-07-12 20:45 2802

Raya Therapeutic announces early-stage R&D collaboration with argenx

MONTREAL, July 12, 2023 /PRNewswire/ -- Raya Therapeutic Inc., ("Raya") a mission-driven company focused on the treatment of neurodegenerative diseases, has entered into an early-stage R&D collaboration with argenx. The collaboration focuses on testing combinations of Raya's pipeline of targeted ...

2023-07-12 19:07 2258

Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division

BOSTON, July 12, 2023 /PRNewswire/ -- Medicilon, a leading one-stop pharmaceutical preclinical R&D service platform CRO, recently appointed Dr.Liu Jian as the President of Drug Discovery Division. Medicilon recognizes the importance of drug discovery as the cornerstone of new drug innovation. Wit...

2023-07-12 18:46 2419
1 ... 100101102103104105106 ... 320